Back

Clinical and pathological characteristics of thin cutaneous melanomas with rapid recurrence.

Bhave, P.; Wong, T.; Margolin, K.; Hoeijmakers, L.; Mangana, J.; Vitale, M. G.; Ascierto, P. A.; Maurichi, A.; Santinami, M.; Heddle, G.; Allayous, C.; Lebbe, C.; Kattak, A.; Forchhammer, S.; Kessels, J. I.; Lau, P.; Lo, S. N.; Papenfuss, A. A.; McArthur, G. A.

2026-04-06 oncology
10.64898/2026.04.04.26350182 medRxiv
Show abstract

Background: Although thin, T1 melanomas have an excellent cure rate with surgery alone, >25% of melanoma deaths originate from thin melanomas (TMs). There is, therefore, an urgent need to improve the identification and management of patients with TMs at high risk of recurrence. Methods: Patients with T1 melanoma and recurrence [&le;] 2 years of diagnosis (T1 rapid group) were compared to patients with T1 melanoma and recurrence [&ge;]10 years after diagnosis (T1 late group). Results: 442 patients from 14 sites were included: 310 and 132 patients in the T1 rapid and late groups, respectively. Median age at primary melanoma diagnosis was 51 years [15-85], 272 (62%) male, 254 (58%) superficial spreading and 101 (23%) head/neck primary. The majority (73%) of recurrences in the T1 rapid group were locoregional. Using univariable logistic regression analysis, age >65 years (p<0.0001), lentigo maligna (LM) melanoma subtype (p=0.025), head/neck primary site (p=0.0065), mitoses [&ge;]1/mm2 (p=0.0181) and ulceration (p=0.0087) were significantly associated with T1 rapid recurrence compared to T1 late recurrence. Using multivariable analysis, age >65 years (p=0.0010), mitoses [&ge;]1/mm2 (p=0.049) and ulceration (p=0.037) remained significant. Conclusions: Rapid recurrence of TM is associated with age >65 years, LM subtype, head/neck primary site, mitoses [&ge;]1/mm2 and ulceration.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.2%
14.6%
2
PLOS ONE
4510 papers in training set
Top 15%
12.7%
3
British Journal of Cancer
42 papers in training set
Top 0.2%
6.5%
4
European Journal of Cancer
10 papers in training set
Top 0.1%
4.9%
5
BMJ Open
554 papers in training set
Top 4%
4.4%
6
Scientific Reports
3102 papers in training set
Top 27%
4.4%
7
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.1%
4.0%
50% of probability mass above
8
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.1%
3.7%
9
Annals of Oncology
13 papers in training set
Top 0.3%
2.6%
10
Frontiers in Oncology
95 papers in training set
Top 2%
2.4%
11
PLOS Medicine
98 papers in training set
Top 2%
1.9%
12
Cancer Medicine
24 papers in training set
Top 0.6%
1.9%
13
BMC Cancer
52 papers in training set
Top 1%
1.9%
14
Nature Communications
4913 papers in training set
Top 50%
1.7%
15
JAMA Network Open
127 papers in training set
Top 2%
1.7%
16
Journal of Translational Medicine
46 papers in training set
Top 0.9%
1.7%
17
OncoImmunology
22 papers in training set
Top 0.2%
1.4%
18
Experimental Eye Research
30 papers in training set
Top 0.4%
1.4%
19
PeerJ
261 papers in training set
Top 9%
1.4%
20
The Journal of Pathology
22 papers in training set
Top 0.2%
1.2%
21
Journal of Clinical Pathology
12 papers in training set
Top 0.3%
1.2%
22
eClinicalMedicine
55 papers in training set
Top 1.0%
1.2%
23
Metabolites
50 papers in training set
Top 0.7%
1.2%
24
Diagnostics
48 papers in training set
Top 2%
0.8%
25
JNCI Cancer Spectrum
10 papers in training set
Top 0.5%
0.8%
26
International Journal of Cancer
42 papers in training set
Top 1%
0.8%
27
Biomolecules
95 papers in training set
Top 2%
0.8%
28
Frontiers in Immunology
586 papers in training set
Top 8%
0.7%
29
JCO Precision Oncology
14 papers in training set
Top 0.5%
0.7%
30
Journal of Clinical Medicine
91 papers in training set
Top 8%
0.5%